Pegylated Liposomal Doxorubicin-Recurrent Ovarian Cancer-Chemotherapy-Phase Iii

Roche study showed that adding Avastin to chemotherapy cut the risk of the disease getting worse in difficult-to-treat recurrent ovarian cancer by half

Roche today announced results from AURELIA, a phase III study that evaluated treatment with Avastin (bevacizumab) in combination with standard chemotherapy (weekly paclitaxel, topotecan or pegylated liposomal doxorubicin) in women with ovarian cancer whose disease had worsened due to resistance to platinum-containing chemotherapy. (Source: Roche Media News) read more..

source:http://www.medworm.com

Memorial Sloan-Kettering Cancer Center,-American Society Of Clinical Oncology-Initial Chemotherapy

Tesetaxel Results as Initial Chemotherapy for Women With Recurrent Breast Cancer to be Highlighted at ASCO

BERKELEY HEIGHTS, N.J., May 22, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) today announced results from the Company's Phase 2 clinical trial using tesetaxel as initial, single-agent chemotherapy in women with advanced breast cancer. The data will be formally presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Tesetaxel is the leading oral taxane in clinical development. The trial is lead by Memorial Sloan-Kettering Cancer Center, New York, NY, in collaboration with three other U.S. centers. (Source: Medical News (via PRIMEZONE)) read more..

source:http://www.medworm.com

The European Association Of Urology-Prostate Cancer

The challenge of prostate cancer drug approval versus reimbursement

Here at the European Association of Urology (EAU) congress in Paris, there are some interesting debates amongst delegates attending the meeting regarding new therapies either recently – or about to be approved – for castrate-resistant prostate cancer (CRPC). For example: … Continue reading ? read more..

source:http://pharmastrategyblog.com

Cancer News-News Wires-Research

J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer

The big cancer news that hit the news wires this morning was not entirely surprising: “Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA (abiraterone acetate) plus prednisone for the treatment of … Continue reading ? read more..

source:http://pharmastrategyblog.com